The process begins with collecting T-cells from the patient. These cells are then genetically engineered in a laboratory to express CARs that specifically target antigens on cancer cells. Once modified, the T-cells are expanded in number and reintroduced into the patient’s bloodstream, where they seek out and destroy the cancer cells.
